P2RX7 inhibition reduces breast cancer induced osteolytic lesions-implications for bone metastasis
Shah, Karan M., Luke Tattersall, Aleana Hussain, Sarah C. Macfarlane, Alexander Williamson, Adelina E. Acosta-Martin, Janine T. Erler, Penelope D. Ottewell, and Alison Gartland. 2022. “P2RX7 Inhibition Reduces Breast Cancer Induced Osteolytic Lesions - Implications for Bone Metastasis,” January. https://doi.org/10.1101/2021.12.31.474644.
Breast cancer metastasis to bone is a major contributor to morbidity and mortality in patients and remains an unmet clinical need. Purinergic signalling via the P2X7 receptor (P2RX7) in the primary tumour microenvironment is associated with progression of several cancers. It has also now become evident that intra-tumoural hypoxia facilitates cancer metastasis and reduces patient survival. In this study, we present data suggesting that hypoxia regulates the expression of P2RX7 in the primary tumour microenvironment; and importantly, inhibition with a selective antagonist (10mg/kg A740003) increased cancer cell death via apoptosis in a E0771/C57BL-6J syngeneic murine model. Furthermore, micro-computed tomography demonstrated reduced number of osteolytic lesions and lesion area following P2RX7 inhibition in absence of overt metastases by decreasing osteoclast numbers. We also demonstrate that activation of P2RX7 plays a role in the secretion of extracellular vesicles (EVs) from breast cancer cells. Mass-spectrometric analyses showed a distinct protein signature for EVs derived from hypoxic compared with normoxic cancer cells which elicit specific responses in bone cells that are associated with pre-metastatic niche formation. Thus, inhibiting P2RX7 provides a novel opportunity to preferentially target the hypoxic breast cancer cells preventing tumour progression and subsequent metastasis to bone